Anavex Life Sciences Corp. (AVXL)
Pre-Market:
| Previous Close | 3.6500 |
| Open | 3.6600 |
| Bid | 3.6400 x 100 |
| Ask | 3.7300 x 100 |
| Day's Range | 3.5300 - 3.8500 |
| 52 Week Range | 3.2500 - 10.4500 |
| Volume | |
| Avg. Volume | 1,322,044 |
| Market Cap | 302.995M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
12 $10 Stocks That Will Triple
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan, the global outlook for securities markets in 2024 suggests a more positive scenario compared to the previous year, with […]
- Insider Monkey
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript February 7, 2024 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.0001, expectations were $-0.14. AVXL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to […]
- Zacks
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
